Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU focuses on safety and effectiveness of pandemic vaccines

This article was originally published in Scrip

Executive Summary

As vaccination campaigns against pandemic flu get underway, the European regulatory and health authorities have laid out their strategy for monitoring the benefit-risk profiles of the various vaccines. The emphasis will be on the rapid detection and reporting of major safety issues such as life-threatening reactions and birth defects, as well as on the effectiveness and immunogenicity of the individual vaccines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC005469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel